Shionogi & Co., Ltd. (TYO: 4507)

Market Cap	1.90T
Revenue (ttm)	418.51B
Net Income (ttm)	154.57B
Shares Out	850.69M
EPS (ttm)	180.65
PE Ratio	12.37
Forward PE	11.52
Dividend	58.00 (2.60%)
Ex-Dividend Date	Mar 28, 2025

Volume	1,262,300
Average Volume	2,030,985
Open	2,216.00
Previous Close	2,226.50
Day's Range	2,212.00 - 2,238.50
52-Week Range	1,944.67 - 2,712.33
Beta	0.28
RSI	56.73
Earnings Date	Jan 31, 2025

About Shionogi &

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1878
• Employees: 4,959
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4507

Financial Performance

In 2023, Shionogi &'s revenue was 435.08 billion, an increase of 1.97% compared to the previous year's 426.68 billion. Earnings were 162.03 billion, a decrease of -12.40%.